Literature DB >> 3893793

Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial.

R S Engelmeier, J B O'Connell, R Walsh, N Rad, P J Scanlon, R M Gunnar.   

Abstract

It has been suspected that the increased sympathetic activity seen in patients with chronic congestive heart failure from dilated cardiomyopathy may be harmful. We therefore tested the long-term effect of metoprolol on eight patients in a double-blind, randomized protocol and 12 patients in an unblinded, crossover protocol who were treated for 12 months (range 10 to 24), and compared them with 16 similar subjects who were treated with placebo for 10 months (range 6 to 12) in a double-blind, randomized protocol. Patients were followed by serial clinical assessment, treadmill testing, radionuclide ventriculography, and echocardiography. Metoprolol-treated patients had an improvement in mean exercise capacity by 3 mets (p less than .0001) while experiencing a significant improvement in functional classification (p less than .001) during both the double-blind and open-label crossover studies and had an improved ejection fraction during the double-blind study (p less than .02). These improvements were not seen in matched control subjects receiving placebo. Seven of 20 patients receiving long-term metoprolol therapy had resolution of nearly all symptoms of heart failure, doubled their exercise capacity, and had progressive improvement in resting radionuclide left ventricular ejection fraction (12.6 +/- 3% to 26.9 +/- 6%) and echocardiographic left ventricular end-diastolic dimension (7.7 +/- 0.5 to 6.5 +/- 0.5 cm). Only one of 21 patients treated was intolerant of metoprolol. We conclude that metoprolol can be given safely to a select group of patients with dilated cardiomyopathy in doses that substantially reduce both resting and exercise heart rates. Long-term beta-blockade improved functional class and exercise capacity in 14 of 20 patients while producing an exceptional clinical response in seven that was accompanied by improved resting parameters of left ventricular function.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3893793     DOI: 10.1161/01.cir.72.3.536

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  52 in total

1.  The anesthetic management for emergency operation on a patient with dilated cardiomyopathy.

Authors:  Y Fujita; Y Hirabayashi; S Yokosuka; K Miyashita; R Shimizu
Journal:  J Anesth       Date:  1990-07       Impact factor: 2.078

Review 2.  Centrally acting sympatholytic agents in the treatment of congestive heart failure. A review of the literature.

Authors:  A Manmontri; S M MacLeod
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

Review 3.  Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies.

Authors:  Evangeline Tzatzalos; Oscar J Abilez; Praveen Shukla; Joseph C Wu
Journal:  Adv Drug Deliv Rev       Date:  2015-09-30       Impact factor: 15.470

Review 4.  Therapy of idiopathic dilated cardiomyopathy with chronic beta-adrenergic blockade.

Authors:  E M Gilbert; J B O'Connell; M R Bristow
Journal:  Heart Vessels Suppl       Date:  1991

5.  The effect of beta-adrenergic blockade in dilated cardiomyopathy--a questionnaire study in Japan.

Authors:  A Matsumori; M Tominaga; S Handa; Y Fukuchi; A Kitabatake; H Matsuo; S Matsuo; J Mihune; T Nakano; S Nobuoka
Journal:  Heart Vessels Suppl       Date:  1991

Review 6.  Treatment of mild congestive heart failure. The potential for new drugs to reduce the risks.

Authors:  U Ravens; M Wehr
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

Review 7.  Recent developments in the treatment of congestive heart failure.

Authors:  W B Hood
Journal:  Trans Am Clin Climatol Assoc       Date:  1991

Review 8.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

9.  Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol.

Authors:  H Persson; E Rythe'n-Alder; A Melcher; L Erhardt
Journal:  Br Heart J       Date:  1995-08

10.  Metoprolol treatment for two years after coronary bypass grafting: effects on exercise capacity and signs of myocardial ischaemia.

Authors:  H Sjöland; K Caidahl; L Lurje; A Hjalmarson; J Herlitz
Journal:  Br Heart J       Date:  1995-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.